Evogene Ltd
evogene.comWhat Do They Do?
Develops small-molecule candidates for pharmaceutical and agricultural-chemical companies using its computational design platform.
20-F for FY2025, filed Mar 26, 2026
Who Are Their Customers?
It works with pharmaceutical and agricultural-chemical collaborators on product development; partners typically lead experimental development while using ChemPass AI to identify and optimize candidates.
20-F for FY2025, filed Mar 26, 2026
Do Revenues Turn Into Profits?
No. It lost $7.8M in .
20-F for FY2025, filed Mar 26, 2026
How Are They Changing?
Narrower product focus
The older report described technology engines for microbes, small molecules, and genetic elements, supporting products across human health, agriculture and other industries. The latest report narrows work to ChemPass AI and small-molecule products for pharmaceutical and agricultural uses, and says it stopped investing in the other engines.
20-F for FY2022, filed Mar 30, 2023 20-F for FY2025, filed Mar 26, 2026
Shift toward collaborations
The older report described subsidiaries advancing their own product pipelines under licenses from Evogene. The latest report describes industry collaborations in which partners pool resources and usually lead experimental development while Evogene identifies and optimizes candidates.
20-F for FY2022, filed Mar 30, 2023 20-F for FY2025, filed Mar 26, 2026We capitalize on the value of our platform through collaborations with industry partners, pooling resources to drive joint product…View ↗
Loading...
